NPPA extends knee implant price ceiling till November 2025 amid review

The NPPA has extended the ceiling price for knee implants till November 2025 while considering industry pleas for removal, citing rising costs and supply chain issues

knee pain, joint pain
The NPPA had first notified the ceiling price of orthopaedic knee implants in 2017 by invoking extraordinary powers under Paragraph 19 of the Drugs Prices Control Order (DPCO) 2013, for a period of one year. (Photo: AdobeStock)
Sanket Koul New Delhi
2 min read Last Updated : Sep 25 2025 | 6:26 PM IST

Don't want to miss the best from Business Standard?

The National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation for orthopaedic knee implants used in knee replacement systems for at least two more months, till November 2025.
 
In a notification dated September 15, the drug price regulator said the fixed price ceiling shall remain in force for orthopaedic knee implants for a further period of up to two months, that is, till November 15, 2025, unless amended by a subsequent notification.
 
According to the notification, the cost of the primary knee replacement system (titanium alloy coated) has been capped at Rs 51,563. The cost of the revision knee replacement system has been capped at Rs 83,547.
 
The notification comes at a time when manufacturers and industry associations have been submitting representations seeking removal of the ceiling.
 
Reasons cited by them include fluctuations in foreign exchange, increased manpower and freight costs, a rise in the Wholesale Price Index (WPI), and supply chain problems.
 
The regulator added that representations received from manufacturers and industry associations on the subject are being considered by the NPPA.
 
The NPPA had first notified the ceiling price of orthopaedic knee implants in 2017 by invoking extraordinary powers under Paragraph 19 of the Drugs Prices Control Order (DPCO) 2013, for a period of one year.
 
The time limit for this price ceiling has been extended every year since then, with the previous extension announced on September 10 last year.
 
In previous orders, the NPPA had noted unjustified, unreasonable and irrationally high trade margins on orthopaedic knee implants, leading to exorbitant prices that increased out-of-pocket expenses for patients.
 
India is a major consumer of knee implants, with the country recording more than 250,000 knee replacement surgeries every year.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :NPPAKnee implantsorthopaedic implantsMedical devices

First Published: Sep 25 2025 | 6:18 PM IST

Next Story